Keap1 redox-dependent regulation of doxorubicin-induced oxidative stress response in cardiac myoblasts

Toxicology and Applied Pharmacology

Volumn 274, Issue 1, 2014, Pages 107-116

  Nordgren, Kendra K S ^a   Wallace, Kendall B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Autophagy; Cardiotoxicity; Doxorubicin; H9c2; Keap1; Nrf2

Indexed keywords

DOXORUBICIN; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84889608742     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.10.023     Document Type: Article

References (34)

1. Benson D.A., Cavanaugh M., Clark K., Karsch-Mizrachi I., Lipman D.J., Ostell J., Sayers E.W. GenBank. Nucleic Acids Res. 2013, 41:D36-D42. (Database issue).
2. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 2007, 23:15-25.
3. Berthiaume J.M., Wallace K.B. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc. Toxicol. 2007, 7:178-191.
4. Bryan H.K., Olayanju A., Goldring C.E., Park B.K. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem. Pharmacol. 2013, 85:705-717.
5. Carvalho R.A., Sousa R.P., Cadete V.J., Lopaschuk G.D., Palmeira C.M., Bjork J.A., Wallace K.B. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology 2010, 270:92-98.
6. Chen Y., Saari J.T., Kang Y.J. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic. Biol. Med. 1994, 17:529-536.
7. Chularojmontri L., Gerdprasert O., Wattanapitayakul S.K. Pummelo protects doxorubicin-induced cardiac cell death by reducing oxidative stress, modifying glutathione transferase expression, and preventing cellular senescence. Evid. Based Complement. Altern. Med.: eCAM 2013, 2013:254835.
8. Copple I.M., Lister A., Obeng A.D., Kitteringham N.R., Jenkins R.E., Layfield R., Foster B.J., Goldring C.E., Park B.K. Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J. Biol. Chem. 2010, 285:16782-16788.
9. Deavall D.G., Martin E.A., Horner J.M., Roberts R. Drug-induced oxidative stress and toxicity. J. Toxicol. 2012, 2012:645460.
10. Dohrmann M., Schorr A., Hulsenbeck J., Rasmussen T.L., Issinger O.G., Fritz G. Comparative analysis of stress responses of H9c2 rat cardiomyoblasts following treatment with doxorubicin and tBOOH. Exp. Cell Res. 2012, 318:779-788.
11. 2 involves KEAP1 disulfide formation. J. Biol. Chem. 2010, 285:8463-8471.
12. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 1 1966, 50:219-244.
13. Giannerini F., Giustarini D., Lusini L., Rossi R., Di Simplicio P. Responses of thiols to an oxidant challenge: differences between blood and tissues in the rat. Chem. Biol. Interact. 2001, 134:73-85.
14. Guo D., Wu B., Yan J., Li X., Sun H., Zhou D. A possible gene silencing mechanism: hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells. Biochem. Biophys. Res. Commun. 2012, 428:80-85.
15. Guo R., Lin J., Xu W., Shen N., Mo L., Zhang C., Feng J. Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells. Int. J. Mol. Med. 2013, 31:644-650.
16. Han X.Z., Gao S., Cheng Y.N., Sun Y.Z., Liu W., Tang L.L., Ren D.M. Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes. Biosci. Trends 2012, 6:19-25.
17. Harake D., Franco V.I., Henkel J.M., Miller T.L., Lipshultz S.E. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012, 8:647-670.
18. Kwon J., Han E., Bui C.B., Shin W., Lee J., Lee S., Choi Y.B., Lee A.H., Lee K.H., Park C., Obin M.S., Park S.K., Seo Y.J., Oh G.T., Lee H.W., Shin J. Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1-Nrf2-Nqo1 cascade. EMBO Rep. 2012, 13:150-156.
19. Leone T.C., Kelly D.P. Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:175-182.
20. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 1991, 324:808-815.
21. Liu J., Zheng H., Tang M., Ryu Y.C., Wang X. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2541-H2550.
22. Luptak I., Balschi J.A., Xing Y., Leone T.C., Kelly D.P., Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005, 112:2339-2346.
23. Ma Q., He X. Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2. Pharmacol. Rev. 2012, 64:1055-1081.
24. Mettler F.P., Young D.M., Ward J.M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977, 37:2705-2713.
25. Palmeira C.M., Serrano J., Kuehl D.W., Wallace K.B. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim. Biophys. Acta 1997, 1321:101-106.
26. Razani B., Zhang H., Schulze P.C., Schilling J.D., Verbsky J., Lodhi I.J., Topkara V.K., Feng C., Coleman T., Kovacs A., Kelly D.P., Saffitz J.E., Dorn G.W., Nichols C.G., Semenkovich C.F. Fatty acid synthase modulates homeostatic responses to myocardial stress. J. Biol. Chem. 2011, 286:30949-30961.
27. Serrano J., Palmeira C.M., Kuehl D.W., Wallace K.B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim. Biophys. Acta 1999, 1411:201-205.
28. Sorensen K., Levitt G., Bull C., Chessells J., Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J. Clin. Oncol. 1997, 15:61-68.
29. Tatlidede E., Sehirli O., Velioglu-Ogunc A., Cetinel S., Yegen B.C., Yarat A., Suleymanoglu S., Sener G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic. Res. 2009, 43:195-205.
30. Vomhof-Dekrey E.E., Picklo M.J. The Nrf2-antioxidant response element pathway: a target for regulating energy metabolism. J. Nutr. Biochem. 2012, 23:1201-1206.
31. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., Muggia F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979, 91:710-717.
32. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol. Toxicol. 2003, 93:105-115.
33. Wang R., An J., Ji F., Jiao H., Sun H., Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun. 2008, 373:151-154.
34. Zhou S., Palmeira C.M., Wallace K.B. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett. 2001, 121:151-157.